A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)

Trial Profile

A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs JZP 110 (Primary)
  • Indications Narcolepsy; Sleep apnoea syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms TONES 3
  • Sponsors Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 19 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 06 Jun 2017 Results from this trial published in a Jazz Pharmaceuticals Media Release.
    • 06 Jun 2017 According to a Jazz Pharmaceuticals media release, results from this trial were presented 31st Associated Professional Sleep Societies (APSS) Annual SLEEP Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top